|
|||||
|
Pfizer, Roche, Eli Lilly and Bristol Myers-Squibb were among the companies with data out this weekend. Pfizer dominated the samples biz, with $2.7 billion in free meds in 2007. Also: the Medicare doughnut hole begins to shrink, a Pfizer trial is halted early and ultrasound becomes the new front in the abortion wars. Pfizer exec Martin Mackay is decamping for cross-Atlantic rival AstraZeneca, where he’ll be president of R&D, a new position, Dow Jones Newswires reports. Mackay held the same title at Pfizer from 2007 to 2009, but in the wake of the company’s Wyeth acquisition, he split the top job … Merck today highlighted cardiovascular pipeline with six molecules in late-stage development. Among them: anacetrapib — a molecular cousin to a drug Pfizer once had in development. judd nelson july 26, 2009 kate gosselin katelynn cashin kathy castor kelly clarkson kenneth cole shoes kim kardashian krugman labor department ladder scripts lady gaga hermaphrodite picture lanny davis latest high score set leens lodge linda kasabian lockerz lollapalooza lollapalooza 2009 lineup mafia wars best of crates mambo mark bittman mark buehrle match the mug [...] Our colleagues over at the Deal Journal raise an interesting point this afternoon: Even as there’s been a recent flurry of deals in the the U.S. bio-pharma world, a handful of European biotech shops have been sitting unsold on the auction block. Nycomed, of Switzerland, looked into being sold earlier this year, but that didn’t [...] Drug companies are supposed to sell their drugs to Medicaid for the cheapest price they negotiate with purchasers from the private sector. Sometimes they get in trouble and have to pay a lot of money if they fail to do that. The Justice Department said yesterday that the federal government and 16 states are joining two [...] More pharma corporate governance action: Abbott shareholders voted down a proposal calling for a non-binding vote on executive compensation. The company had opposed the measure; the owners of 40% of the company’s shares voted in favor, Dow Jones Newswires reports. Just yesterday, Pfizer shareholders passed a “say on pay” resolution (52% in favor) and J&J shareholders [...] Both Pfizer and Johnson & Johnson held their annual meetings today, which makes for an interesting study in contrasts. Pfizer shareholders voted to give themselves an “advisory vote” on executive compensation, while J&J shareholders voted down a similar proposal, notes Pete Loftus of Dow Jones Newswires. Both votes were close: 52% in favor at Pfizer, versus [...] |
|||||
|
217 queries. 0.481 seconds. |
|||||